SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vion (formerly Oncorx) interesting play on Gene Therapy
An SI Board Since April 1996
Posts SubjectMarks Bans Symbol
370 14 0 VION
Emcee:  Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
270Vion Pharma Reports Patent Office Decision DOW JONES NEWSWIRES NEW HAVEN, Conn.Jim Oravetz-4/22/2002
269What am I missing here? VION is down 18% today, but I don't see any news. IsDave-4/22/2002
268Vion Pharma Will Formally Introduce New CFO Next Week DOW JONES NEWSWIRES NEW HJim Oravetz-3/13/2002
267Vion Begins Phase I Clinical Trial of First Armed TAPET(R) Vector NEW HAVEN, CJim Oravetz-2/25/2002
266It is not true that Melasyn is no longer being manufactured. It is used in produ9wald9-2/25/2002
265Missed this PR, Re: the Hopkins study vionpharm.com Looks like Vion has a bettJim Oravetz-1/3/2002
264Jim: I haven't followed TAPET, but even with the VION bacteria that are LPSscaram(o)uche-12/12/2001
263SemiOT:New Bacteria Target Cancers in Mice hopkinscancercenter.org NOVEMBER 26Jim Oravetz-12/12/2001
262Message 16773728scaram(o)uche-12/11/2001
261CEO outlines Vion Pharmaceuticals' strategy for the next few years Alan KessJim Oravetz-11/8/2001
260Oct. 31 /PRNewswire/ VION today announced results for the third quarter and theJim Oravetz-11/2/2001
259Vion Pharma 3Q Loss 13c/Shr Dow Jones Newswires <pre> Vion PharmaceuticalsJim Oravetz-11/1/2001
258Lots of variables with that one. Don't know if there are typical numbers orJim Oravetz-9/6/2001
257Hey Jim, can you direct me toward any basic description of the different phases Dave-9/6/2001
256siliconinvestor.com <i>NEW HAVEN, Conn., Aug 10, 2001 /PRNewswire via COMDave-8/10/2001
255Revenue $180,992 Net income (3,232,875) Avg shrs (basic) 26,190,356 2Q JimJim Oravetz-8/1/2001
254Vion Begins Triapine Phase 2 Clinical Trial Dow Jones Newswires NEW HAVEN, ConnJim Oravetz-7/23/2001
253Vion wins grant to help develop cancer drugs C.J. Abate, Register Staff July Jim Oravetz-7/13/2001
252Vion Pharmaceuticals Names Koehler Fincl Chief Dow Jones Newswires NEW HAVEN, CoJim Oravetz-7/11/2001
251clinicaltrials.gov VNP20009 in Treating Patients With Advanced Solid Tumors ThJim Oravetz-5/29/2001
250Dear Fellow Stockholder: You are cordially invited to attend the CompaJim Oravetz-5/23/2001
249Vion Pharma Says Canine Trial Shows Tapet Effective NEW HAVEN, Conn. -- Vion PhJim Oravetz-5/23/2001
248www.acvim.org: go to Denver Conference, Research Abstracts, # 82... 82 GENETICAJim Oravetz-5/22/2001
247I'm not complaining or anything, but does anybody know why VION has been skyDave-5/18/2001
246What? Is there some sort of bribe involved? A little over a years worth of $$$Scott H. Davis-5/15/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News